Reference values for plasma concentrations of asymmetrical dimethylarginine (ADMA) and other arginine metabolites in men after validation of a chromatographic method

Clinica Chimica Acta

Volumn 384, Issue 1-2, 2007, Pages 141-148

  Meinitzer, Andreas ^a,b   Puchinger, Markus ^a   Winklhofer Roob, Brigitte M ^b   Rock, Edmond ^c   Ribalta, Josep ^d   Roob, Johannes M ^a   Sundl, Isabella ^b   Halwachs Baumann, Gabriele ^a   März, Winfried ^a,e  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Institute of Molecular Biosciences   (Austria)

^c CRNH AUVERGNE   (France)

^d Unitat de Recerca de Lipids i Arteriosclerosi   (Spain)

^e SYNLAB ACADEMY   (Germany)

Author keywords

ADMA; Methylated arginines; Plasma; Reference values

Indexed keywords

ARGININE; ARGININE DERIVATIVE; DIMETHYLARGININE; EDETIC ACID; HOMOARGININE; N(G),N(G) DIMETHYLARGININE; UNCLASSIFIED DRUG;

ARTICLE; CHROMATOGRAPHY; GROUPS BY AGE; KRUSKAL WALLIS TEST; PRIORITY JOURNAL; REFERENCE VALUE; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ARGININE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HOMOARGININE; HUMANS; MALE; MIDDLE AGED;

EID: 34547901469     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.07.006     Document Type: Article

References (41)

1. Moncada S., Palmer R.M., and Higgs E.A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43 (1991) 109-142
2. Verma S., and Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105 (2002) 546-549
3. Vallance P., Leone A., Calver A., Collier J., and Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339 (1992) 572-575
4. Valkonen V.P., and Laaksonen R. Asymmetric dimethylarginine (ADMA) and acute vascular events. Clin Chim Acta 348 (2004) 9-17
5. Meinitzer A., Seelhorst U., Wellnitz B., et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the ludwigshafen risk and cardiovascular health study). Clin Chem 53 (2007) 273-283
6. Leiper J., and Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43 (1999) 542-548
7. Ghosh S.K., Paik W.K., and Kim S. Purification and molecular identification of two protein methylases I from calf brain. Myelin basic protein- and histone-specific enzyme. J Biol Chem 263 (1988) 19024-19033
8. Pettersson A., Uggla L., and Backman V. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 692 (1997) 257-262
9. Boger R.H., Lentz S.R., Bode-Boger S.M., Knapp H.R., and Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 100 (2001) 161-167
10. Paiva H., Laakso J., Laine H., Laaksonen R., Knuuti J., and Raitakari O.T. Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. J Am Coll Cardiol 40 (2002) 1241-1247
11. Teerlink T., Nijveldt R.J., de Jong S., and van Leeuwen P.A. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 303 (2002) 131-137
12. Kielstein J.T., Bode-Boger S.M., Frolich J.C., Ritz E., Haller H., and Fliser D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 107 (2003) 1891-1895
13. Bae S.W., Stuhlinger M.C., Yoo H.S., et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95 (2005) 729-733
14. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 43 (2005) 1130-1138
15. Vishwanathan K., Tackett R.L., Stewart J.T., and Bartlett M.G. Determination of arginine and methylated arginines in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 748 (2000) 157-166
16. Tsikas D., Schubert B., Gutzki F.M., Sandmann J., and Frolich J.C. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J Chromatogr B Anal Technol Biomed Life Sci 798 (2003) 87-99
17. Albsmeier J., Schwedhelm E., Schulze F., Kastner M., and Boger R.H. Determination of NG,NG-dimethyl-l-arginine, an endogenous NO synthase inhibitor, by gas chromatography-mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 809 (2004) 59-65
18. Martens-Lobenhoffer J., Krug O., and Bode-Boger S.M. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom 39 (2004) 1287-1294
19. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., and Boger R.H. Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects. Eur J Clin Investig 35 (2005) 622-626
20. Martens-Lobenhoffer J., and Bode-Boger S.M. Measurement of asymmetric dimethylarginine (ADMA) in human plasma: from liquid chromatography estimation to liquid chromatography-mass spectrometry quantification. Eur J Clin Pharmacol 62 (2006) 61-68
21. Guidance, for, industry. Bioanalytical method validation, us department of health and human services, food and drug administration, center for drug evaluation and research (CDER), center for biologics evaluation and research (CBER) (May 2001)
22. Rock E., Winklhofer-Roob B.M., Ribalta J., et al. Vitamin A, vitamin E and carotenoid status and metabolism during ageing: functional and nutritional consequences (VITAGE PROJECT). Nutr Metab Cardiovasc Dis 11 (2001) 70-73
23. Kumanyika S.K., Landis J.R., Matthews-Cook Y.L., Almy S.L., and Boehmer S.J. Systolic blood pressure trends in US adults between 1960 and 1980: influence of antihypertensive drug therapy. Am J Epidemiol 148 (1998) 528-538
24. Solberg H.E. International federation of clinical chemistry (IFCC), scientific committee, clinical section, expert panel on theory of reference values, and international committee for standardization in haematology (ICSH), standing committee on reference values. Approved recommendation (1986) on the theory of reference values. Part 1. The concept of reference values. J Clin Chem Clin Biochem 25 (1987) 337-342
25. Boger R.H., Bode-Boger S.M., Szuba A., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
26. Ogawa T., Kimoto M., and Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-l-arginine to l-citrulline in rats. Biochem Biophys Res Commun 148 (1987) 671-677
27. Ogawa T., Kimoto M., and Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 264 (1989) 10205-10209
28. Tran C.T., Leiper J.M., and Vallance P. The DDAH/ADMA/NOS pathway. Atheroscler Suppl 4 (2003) 33-40
29. Leiper J.M. The DDAH-ADMA-NOS pathway. Ther Drug Monit 27 (2005) 744-746
30. Marescau B., Nagels G., Possemiers I., et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46 (1997) 1024-1031
31. Anderstam B., Katzarski K., Bergstrom J., and Serum levels of N.G. NG-dimethyl-l-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8 (1997) 1437-1442
32. Fleck C., Schweitzer F., Karge E., Busch M., and Stein G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta 336 (2003) 1-12
33. Ryan W.L., and Wells I.C. Homocitrulline and homoarginine synthesis from lysine. Science 144 (1964) 1122-1127
34. Stuhlinger M.C., Oka R.K., Graf E.E., et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108 (2003) 933-938
35. Wanby P., Brattstrom L., Brudin L., Hultberg B., and Teerlink T. Asymmetric dimethylarginine and total homocysteine in plasma after oral methionine loading. Scand J Clin Lab Invest 63 (2003) 347-353
36. Doshi S., McDowell I., Goodfellow J., et al. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia. Metabolism 54 (2005) 351-360
37. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
38. Abbasi F., Asagmi T., Cooke J.P., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
39. Stuhlinger M.C., Abbasi F., Chu J.W., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Jama 287 (2002) 1420-1426
40. Lundman P., Eriksson M.J., Stuhlinger M., Cooke J.P., Hamsten A., and Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38 (2001) 111-116
41. Yoo J.H., and Lee S.C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158 (2001) 425-430